Partnering with Anthos to Build a High-Performing Clinical Organisation

Posted January 30, 2026

Our Approach

We began with a detailed alignment process focused on understanding the commercial and clinical risk behind each hire.

Working closely with leadership, we defined the capabilities, behaviours, and leadership profile required to succeed in a fast-moving and high-accountability environment. We clarified what success looked like across Clinical Operations, Biometrics, Quality, Supply Chain, and TMF, and aligned hiring priorities to Phase III milestones.

A clear Statement of Work was agreed, setting out deliverables, timelines, and direct access to the leadership team. This allowed for fast decision-making, tight feedback loops, and a highly focused search strategy.

Execution

For every role, Elixir delivered a minimum of six highly relevant candidates within four weeks or less. Every appointment was made from the initial shortlist.

A pivotal hire was the appointment of Sharon Arnold as SVP Development Operations. In this role, Sharon led and integrated Clinical Operations, Biometrics, Clinical Quality, Supply Chain, and TMF.

As the organisation scaled, Elixir partnered with Anthos to build a high-performing clinical and development organisation, delivering hires across the following roles:

  • Director, Clinical Program Lead
  • Executive Director, Clinical Operations
  • Executive Director, Head of Biostatistics and Data Analytics
  • Head of Clinical Quality Management
  • Director, Clinical Supply Management
  • Senior Manager, Site Management
  • Associate Director, Clinical Trial Management
  • Head of Statistical Programming
  • Senior Clinical Trial Associate
  • Senior Clinical Trial Manager
  • Senior Clinical Trial Manager
  • TMF Subject Matter Expert

Outcome

The leadership team assembled during this period re-established control over trial execution, improved site engagement, and accelerated patient enrolment.

Anthos progressed its programs with renewed operational confidence and ultimately achieved a successful acquisition by Novartis for $3.1bn.

The team built during this phase played a critical role in positioning the business to be acquisition-ready on both the clinical and operational fronts.